Rubicon Carbon Unveils the Rubicon Rated Tonne, the First-Ever Carbon Credit Portfolio Rated by BeZero Carbon, Receiving an AA port Rating
18.6.2025 14:00:00 CEST | Business Wire | Press Release
Rubicon Carbon, a carbon credit management firm, today launched the Rubicon Rated Tonne (RRT), a new set of curated carbon credit portfolios for customers seeking credits with third-party verification. The first of these portfolios has received an AAport rating by BeZero Carbon, a leading independent carbon ratings agency, through its new Portfolio Rating framework, indicating that each portfolio credit has a very high likelihood of achieving one tonne of CO2e avoidance or removal.
Rubicon Carbon develops portfolios of carbon credits to minimize the risks associated with carbon credit purchases, build buyer confidence, and catalyze investment in climate resilience projects. A complement to Rubicon Carbon’s existing offering, the first RRT includes carbon removal, nature-based, and super-pollutant elimination projects. All of these projects have passed the company’s stringent due diligence process and, in addition, have received an AAport rating based on the quality of their underlying credits.
“We believe that growing the voluntary carbon market will require cooperation among industry leaders to build buyer confidence among companies seeking to make progress towards their sustainability goals,” said Tom Montag, CEO of Rubicon Carbon. This partnership underscores Rubicon Carbon’s and BeZero’s shared commitment to transparency and environmental integrity. With risk-adjustment already built into the Rubicon Carbon Tonne, we’re excited to bring third-party validation and rigor to this innovative approach.
To qualify for a BeZero portfolio rating, all individual credits must be rated B or higher and have an additionality risk rating of ‘b’ or above. Additionally, at least 25% of the credits must match the portfolio's overall rating, none may be more than two notches below it, and lower-rated projects require additional credit retirements based on BeZero’s discount schedule to ensure carbon integrity.
By purchasing carbon credit portfolios that incorporate risk adjustment, buyers gain greater confidence in determining how many credits they need to effectively address their emissions, verified by BeZero’s independent portfolio rating. The portfolio rating is time-stamped and updated regularly to ensure it reflects the latest portfolio composition.
Tommy Ricketts, BeZero Carbon’s CEO and co-founder, said, “We are thrilled to be partnering with Rubicon Carbon’s team to bring a first-of-its-kind innovation for carbon markets, combining their portfolio of credits with BeZero’s Portfolio Rating methodology.”
Ricketts added, “The BeZero Carbon Rating is an independent, live, public assessment of the risks individual projects face in achieving a tonne of CO2e. The portfolio uses our ratings and applies strict rules to give buyers greater confidence to make credible, risk-adjusted claims. It is a piece of market innovation that acknowledges the reality that not all carbon credits are created equal, while also recognizing the importance of investing in high-quality carbon projects to drive meaningful climate action.”
This launch is the latest in Rubicon Carbon’s continued efforts to bring institutional-quality carbon solutions to market, helping global organizations invest in credible, scalable, and science-based climate action. For more information on Rubicon Carbon, visit the website or follow on LinkedIn.
About Rubicon Carbon:
Rubicon Carbon is a carbon credit management firm that empowers the world’s largest enterprises to achieve their sustainability goals by addressing carbon emissions and driving global climate finance. Backed by TPG Rise Climate and led by top executives from across finance, technology, and climate science, Rubicon Carbon delivers innovative carbon credit solutions to global businesses while unlocking carbon avoidance and removal projects at scale, all backed by rigorous in-house scientific diligence. For more information, visit www.rubiconcarbon.com.
About BeZero:
BeZero is the carbon ratings agency. Its ratings and risk products equip world-leading organisations with the knowledge, tools and confidence to make better climate decisions. Its aim is to scale investment in environmental markets that deliver a sustainable future.
Visit bezerocarbon.com and follow BeZero on LinkedIn and X to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618837533/en/
Contacts
For more information, please contact:
Rubicon Carbon Media Relations
rubiconcarbon@berlinrosen.com
+1 (714) 300-8748
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom